Cargando…
Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018
This cross-sectional study of health claims from patients with private insurance examines trends in the cost of entecavir prescribed for chronic hepatitis B treatment.
Autores principales: | Alpern, Jonathan D., Joo, Heesoo, Link, Ben, Ciaccia, Antonio, Stauffer, William M., Bahr, Nathan C., Leventhal, Thomas M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783269/ https://www.ncbi.nlm.nih.gov/pubmed/35061044 http://dx.doi.org/10.1001/jamanetworkopen.2021.44521 |
Ejemplares similares
-
Spending and Out-of-Pocket Prices for Brand-Name Drugs Among Commercially Insured Individuals in Massachusetts, 2015-2017
por: Aaron, Micah B., et al.
Publicado: (2021) -
Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
por: DiStefano, Michael J., et al.
Publicado: (2023) -
The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia
por: Spargo, Andrew, et al.
Publicado: (2021) -
Out-of-pocket spending for contraceptives in Latin America
por: Garraza, Lucas Godoy, et al.
Publicado: (2020) -
Out-of-Pocket Spending for Influenza Hospitalizations in Medicare Advantage
por: Chua, Kao-Ping, et al.
Publicado: (2021)